ABSTRACT
Objective@#To understand sensory characteristics and its correlation with behavioral problems among children with autism spectrum disorder (ASD), so as to provide reference basis for early diagnosis and comprehensive intervention of ASD children.@*Methods@#Using cross sectional survey, 193 ASD children trained by Nantong rehabilitation institutions were recruited from September 2021 to February 2022. All children were investigated with the Short Sensory Profile (SSP) and Parent Symptom Questionnaire (PSQ).@*Results@#Among the 193 ASD children, 106 (54.9%) children had abnormal sensory characteristics, including 45 (23.3%) with possible abnormalities and 61 (31.6%) with obvious abnormalities. The abnormal rate of auditory filtering was the highest in the seven dimensions, reaching 85.0%, followed by low strength/weakness, motor sensitivity, taste/smell sensitivity, low response/seeking sensation, vision/hearing sensitivity and tactile sensitivity. The total incidence of sensory abnormalities was 93.3%. There were significant differences in six dimensions of PSQ scale scores of ASD children with different degrees of sensory abnormalities, including conduct problems, learning problems, psychosomatic disorders, impulsive hyperactivity, anxiety and hyperactivity index ( H =38.89, 38.90, 19.53, 46.34, 34.54, 54.90, P <0.01). With the aggravation of sensory abnormalities in children with ASD, the scores of all dimensions of the PSQ scale increased significantly. The total score of SSP was negatively correlated with the six dimensions of conduct problems, learning problems, psychosomatic disorders, impulsive hyperactivity, anxiety and hyperactivity index in PSQ ( r =-0.53, -0.50, -0.32, -0.55, -0.43, -0.61, P <0.01).@*Conclusion@#ASD children generally have sensory abnormalities, which coincide with severity of behavioral problems. There is a positive correlation between sensory abnormalities and behavioral problems in ASD children. More attention should be paid to the abnormal sensory characteristics of children with ASD in the future diagnosis and treatment process.
ABSTRACT
Esophageal cancer is one of the most common gastrointestinal cancers, and chemoradiotherapy is an important part of the multidisciplinary treatment for this disease.In recent years,18Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET-CT) is widely used in esophageal cancer for delineation of gross tumor volume, local boost irradiation in the late stage of radiotherapy, and assessment of the pathologic remission rate after neoadjuvant chemoradiotherapy, response to definitive chemoradiotherapy, and prognosis.In this article, we review the application of FDG PET-CT in the chemoradiotherapy for esophageal cancer.
ABSTRACT
Esophageal cancer is a common gastrointestinal cancer in China with poor prognosis.Radiotherapy is the main treatment of esophageal cancer,and radiosensitivity of the tumor cell is a significant reason for the efficacy of radiotherapy.Mesenchymal-epithelial transition factor (c-Met) and its signaling pathway play an significant role in tumorigenesis,development,invasion,metastasis and treatment resistance.This review summarizes the association between expression of c-Met and radiosensitivity in esophageal cancer.
ABSTRACT
The key of individualized therapy is that using molecular markers to select more suitable drug.At present,some studies have confirmed that certain molecular markers can predict the efficacy of the drugs.For example,cetuximab is beneficial in patients with K-ras wild-type colorectal cancer,gefitinib and erlotinib are beneficial in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer( NSCLC),imatinib is beneficial in patients with C-KIT gene-positive gastrointestinal stromal tumor.In terms of safety,the promoter polymorphism of UDP glucuronosyltransferase 1 polypeptide A1 ( UGT1 A1 ) can predict the toxicity of irinotecan.
ABSTRACT
The combination of chemotherapy, radiotherapy and targeted therapies are considered to be major treatments for metastatic pancreatic cancer. At present, the target therapy-related medications include mainly antagonist of epidermal growth factor receptor, monoclonal antibody of vascular endothelial growth factor and so on. Erlotinib combined with gemcitabine has been demonstrated to prolong the survival of patients with pancreatic cancer.